Renowned Cleveland Clinic Urologist Dr. Eric Klein discusses Active Surveillance. Dr. Klein answers the questions: “What do I actually do while I’m on Active Surveillance?” What tests should I be taking and how often? How do I know if I qualify for Active Surveillance? What indicators will tell me that I must go off Active Surveillance and seek active treatment? Dr. Klein indicated that 15% of Gleason 6s have a molecular make up which may indicate the presence of a more aggressive cancer and in his opinion, genomic testing is critical to identify those cancers. Click here to view.
November 2019 Awareness Night Active Surveillance Decisions (Why, Who, How, and When you know it’s time to be treated) Dr. Danny Vesprini, MD, MSc, FRCPC Affiliate Scientist, Biological Sciences, Odette Cancer Research Program, Sunnybrook Research Institute Radiation Oncologist, Dept. of Radiation Oncology, Sunnybrook Odette Cancer Centre Asst. Prof., Dept. of Radiation Oncology, U. of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 1:04:57 minutes <
Noted urologic surgeon Bert Vorstman, MD, MS, FAAP, FRACS, FACS today has issued a stinging report regarding the unreliable PSA test, the mislabeling of the common Gleason 6 prostate disease as a cancer, and the misrepresentation that the radical (robotic) prostatectomy treatment is scientifically proven to be safe and effective – a charade that represents an outrageous and shameful trifecta of abominations. Read the article.
Data from the survival outcomes of patients support the use of active surveillance in low risk and intermediate risk cases of Gleason 6 but not Gleason 7 prostate cancer. Multiparametric magnetic resonance imaging and novel biomarkers might be vital in detecting favorable Gleason 7 disease. Read the article here.